Physician profile
Nirav Parikh
NPI 1811331184
$2,026.36
in general payments reported to CMS, 2019-2025
23 companies · $173 in 2025
The $173 reported for 2025 was more than what a typical Hospitalist provider received nationally (typical 2025 total: $85.87).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $149 · 2020: $19.54 · 2021: $361 · 2022: $197 · 2023: $465 · 2024: $663 · 2025: $173.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,300.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,299.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $421.52 | 2024-2025 | Krystexxa |
| Janssen Pharmaceuticals, INC | $247.60 | 2019-2023 | Xarelto |
| Glaxosmithkline, LLC. | $245.79 | 2021-2022 | |
| Horizon Therapeutics Plc | $189.99 | 2023 | Krystexxa |
| Abbott Laboratories | $105.17 | 2024 | Mitraclip |
| Alexion Pharmaceuticals, INC. | $104.49 | 2021 | |
| Astrazeneca Pharmaceuticals Lp | $97.25 | 2023 | Lokelma, Farxiga |
| Otsuka America Pharmaceutical, INC. | $85.66 | 2019-2024 | Jynarque |
| Bayer Healthcare Pharmaceuticals INC. | $84.81 | 2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $71.12 | 2023-2024 | Jardiance |
| Novo Nordisk INC | $65.55 | 2024-2025 | Rybelsus, Ozempic, Wegovy |
| Pfizer INC. | $48.64 | 2023-2024 | |
| Baxter Healthcare | $43.88 | 2023 | |
| Lilly USA, LLC | $34.31 | 2025 | Zepbound |
| Cardiva Medical, INC. | $32.18 | 2022-2023 | Cardiva Vascade 6/7f Vcs |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Verona Pharma, INC. | $25.70 | 2025 | Ohtuvayre |
| Merck Sharp & Dohme LLC | $21.36 | 2022 | |
| Ardelyx, INC. | $20.14 | 2025 | Ibsrela |
| Aroa Biosurgery Incorporated | $19.54 | 2020 | |
| Lemaitre Vascular, INC. | $16.77 | 2023 | Artegraft Vascular Graft |
| Abbvie INC. | $16.70 | 2021 | |
| Calliditas Therapeutics US INC. | $14.87 | 2023 | Tarpeyo |
| Kci USA, INC. | $13.32 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nirav Parikh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.